Navigation Links
SyntheMed Announces FDA Clearance of SinusShield(TM)
Date:11/19/2008

awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve market potential, distribution strategies, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. SyntheMed to Present at the Acumen BioFin Conference
3. SyntheMed Files Universal Shelf Registration
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed Announces New Management Appointments
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8